SK Bioscience Partners with US CDC for Injectable Rotavirus Vaccine Development

SK Bioscience is joining forces with the U.S. Centers for Disease Control and Prevention (CDC) to advance the development of a novel injectable rotavirus vaccine. This collaboration marks a significant step for the South Korean biotechnology firm in its pursuit of innovative vaccine solutions.

The company announced on June 9 that it has entered into a technology transfer agreement with the CDC. Under this agreement, SK Bioscience will utilize a rotavirus vaccine candidate that the CDC has already developed and progressed through Phase 1 clinical trials. This partnership leverages the CDC's research and development expertise with SK Bioscience's manufacturing and commercialization capabilities.

Following the technology acquisition, SK Bioscience plans to concentrate on optimizing the production process to enhance manufacturing efficiency. The company aims to streamline the development pipeline, ensuring the vaccine candidate can be produced at scale effectively. Once the process development is complete, SK Bioscience will proceed with further clinical trials and seek regulatory approvals necessary for market entry.

This initiative underscores SK Bioscience's commitment to addressing global health challenges through vaccine innovation. Rotavirus is a leading cause of severe diarrheal disease among infants and young children worldwide, and the development of an effective injectable vaccine could significantly improve public health outcomes.